張志華 溫雅蘭 羅紅玉
[摘要]目的 探討戊酸雌二醇片/雌二醇環(huán)丙孕酮片復合包裝聯(lián)合艾司西酞普蘭在圍絕經(jīng)期抑郁癥治療中的應用。方法 選取贛州市第三人民醫(yī)院2016年1月~2017年12月收治的60例圍絕經(jīng)期抑郁癥患者作為研究對象,按照隨機數(shù)字表法分為研究組(30例)與對照組(30例)。研究組采用戊酸雌二醇片/雌二醇環(huán)丙孕酮片復合包裝+艾司西酞普蘭治療,對照組采用艾司西酞普蘭治療。比較兩組的漢密爾頓抑郁量表評分(HAMD)、治療效果及不良反應發(fā)生情況。結果? 研究組治療后第4、8、12周的HAMD評分均低于對照組,差異有統(tǒng)計學意義(P<0.05);研究組的治療總有效率高于對照組,差異有統(tǒng)計學意義(P<0.05);研究組的不良反應總發(fā)生率低于對照組,差異有統(tǒng)計學意義(P<0.05)。結論? 戊酸雌二醇片/雌二醇環(huán)丙孕酮片復合包裝聯(lián)合艾司西酞普蘭在治療圍絕經(jīng)期抑郁癥中的應用效果顯著,能降低患者抑郁狀況,提升治療效果,且具有較低不良反應發(fā)生率。
[關鍵詞]戊酸雌二醇片/雌二醇環(huán)丙孕酮片復合包裝;艾司西酞普蘭;圍絕經(jīng)期抑郁癥;療效
[中圖分類號] R749.4+2? ? ? ? ? [文獻標識碼] A? ? ? ? ? [文章編號] 1674-4721(2020)5(c)-0166-04
Curative effect observation of Climen combined with Escitalopram in the treatment of perimenopausal depression
ZHANG Zhi-hua1? ?WEN Ya-lan2? ?LUO Hong-yu3
1. Department of Obstetrics and Gynecology, Ganzhou Third People′s Hospital in Jiangxi Province, Ganzhou? ?341000, China; 2. Department of Gynecology and Obstetrics, Ganzhou Hospital of Traditional Chinese Medicine in Jiangxi Province, Ganzhou? ?341000, China; 3. Department of Obstetrics and Gynecology, Ganzhou Maternal and Child Health Hospital in Jiangxi Province, Ganzhou? ?341000, China
[Abstract] Objective To explore the application of Estradiol Valproate Tablets/Escitalopram Tablets and Escitalopram in the treatment of perimenopausal depression. Methods A total of 60 patients with perimenopausal depression in Ganzhou Third People′s Hospital from January 2016 to December 2017 were selected as the subjects of the study. According to the random number table method, the patients were divided into the study group (30 cases) and the control group (30 cases). The study group was treated with Estradiol Valproate Tablets/Escitalopram Tablets + Escitalopram Tablets, while the control group was treated with Escitalopram. The Hamilton depression scale (HAMD), therapeutic effect and adverse reactions were compared between the two groups. Results The HAMD scores of the study group at the 4th, 8th and 12th weeks after treatment were lower than those of the control group, the differences were statistically significant (P<0.05). The total effective rate of the study group was higher than that of the control group, the difference was statistically significant (P<0.05). The total incidence of adverse reactions in the study group was lower than that in the control group, the difference was statistically significant (P<0.05). Conclusion Estradiol Valerate Tablets/Escitalopram Tablets combined with Escitalopram are effective in the treatment of permenopausal depression, which can reduce the depression status of patients, improve the therapeutic effect, and have a lower incidence of adverse reactions.
目前,關于抑郁癥的發(fā)病原因臨床尚不明確,但普遍認為抑郁癥與患者中樞神經(jīng)系統(tǒng)有著密切關系,其中,5-羥色胺(5-HT)及去甲腎上腺素(NE)的平衡被破壞,濃度下降則極易誘發(fā)抑郁癥,并促使抑郁癥不斷發(fā)展[11-12]。因此,臨床上多采用5-HT再攝取抑制劑(SSRIs)進行抗抑郁治療[13],其中,艾司西酞普蘭是應用最廣泛的藥物之一。艾司西酞普蘭對5-HT的被回收產(chǎn)生抑制作用,以提升5-HT的濃度,從而加強其神經(jīng)傳導功能,有效減輕抑郁癥狀[14]。同時,抑郁癥的產(chǎn)生與圍絕經(jīng)期女性體內(nèi)的雌激素減少有關,因此,需要使用相應藥物進行雌激素補充[15]。作為一種雌孕激素復合制劑,戊酸雌二醇片/雌二醇環(huán)丙孕酮片復合包裝適用于圍絕經(jīng)期婦女雌激素缺乏出現(xiàn)的一系列癥狀治療,該藥能有效調(diào)節(jié)患者月經(jīng)周期,維持其月經(jīng)正常,平衡患者體內(nèi)激素,從而改善抑郁等各種精神疾病,其已成為目前公認的能有效治療女性圍絕經(jīng)抑郁癥的藥物之一。戊酸雌二醇片/雌二醇環(huán)丙孕酮片復合包裝可與抗抑郁藥物聯(lián)合使用,能夠在調(diào)節(jié)患者體內(nèi)激素水平的同時,提升5-HT濃度,加強抗抑郁作用,有效緩解患者抑郁癥狀,提升治療效果,從而顯著改善圍絕經(jīng)期抑郁癥狀,促進患者痊愈,促使女性保持健康心理,提高其生活質(zhì)量。本研究分析戊酸雌二醇片/雌二醇環(huán)丙孕酮片復合包裝聯(lián)合艾司西酞普蘭治療圍絕經(jīng)期抑郁癥的效果,結果顯示,經(jīng)治療后,患者的抑郁狀況明顯減輕,提示采用戊酸雌二醇片/雌二醇環(huán)丙孕酮片復合包裝聯(lián)合艾司西酞普蘭治療圍絕經(jīng)期抑郁癥能有效改善患者負性情緒,幫助其構建良好心態(tài),從而緩解患者抑郁癥狀。在治療圍絕經(jīng)期抑郁癥方面,戊酸雌二醇片/雌二醇環(huán)丙孕酮片復合包裝與艾司西酞普蘭聯(lián)合使用的效果顯著。同時,采用戊酸雌二醇片/雌二醇環(huán)丙孕酮片復合包裝聯(lián)合艾司西酞普蘭治療圍絕經(jīng)期抑郁癥,患者出現(xiàn)嗜睡、乳房疼痛等不良反應較少,但在使用過程中,需要根據(jù)患者的具體情況調(diào)整藥物劑量,以有效避免兩種藥物不良反應情況發(fā)生。
綜上所述,克戊酸雌二醇片/雌二醇環(huán)丙孕酮片復合包裝聯(lián)合艾司西酞普蘭治療圍絕經(jīng)期抑郁癥能夠提高效果,改善患者生活質(zhì)量,值得臨床推廣使用。但在臨床治療中,需要根據(jù)患者具體情況調(diào)節(jié)給藥劑量,以免藥物不良反應對患者健康造成影響。
[參考文獻]
[1]黃宏麗,沈捷雯,董亞蘭, 等.針藥并用對圍絕經(jīng)期抑郁癥患者HAMD積分、SDS積分及HPO軸的影響[J].上海針灸雜志,2017,36(6):705-710.
[2]李月娥,徐上知,呂淑云,等.維吾爾族、漢族圍絕經(jīng)期抑郁癥患者女性激素水平和社會心理因素的對比[J].中國婦幼保健,2015,30(35):6333-6336.
[3]崔鶴,婁小平.自我管理對圍絕經(jīng)期抑郁癥患者抑郁狀態(tài)及生存質(zhì)量的影響[J].河南醫(yī)學研究,2016,25(8):1527-1528.
[4]張家秀,韓利,瞿娜.雌激素受體α在圍絕經(jīng)期女性抑郁癥發(fā)病中的作用及機制[J].中國婦幼保健,2015,30(15):2327-2328.
[5]趙寧,雷勇,賈衛(wèi)靜,等.小劑量激素治療對圍絕經(jīng)期女性生活質(zhì)量和激素水平的影響[J].河北醫(yī)藥,2016,38(18):2808-2810.
[6]陳軍良,駱建忠,姜誠勇,等.圍絕經(jīng)期婦女抑郁癥發(fā)生情況及相關因素分析[J].中國慢性病預防與控制,2014,22(6):672-674.
[7]王相蘭,陶炯,鐘智勇,等.圍絕經(jīng)期女性靜息狀態(tài)下丘腦功能連接與性激素和抑郁癥狀的相關性[J].中華醫(yī)學雜志,2015,95(39):3190-3195.
[8]Li S,Li ZF,Wu Q,et al.A Multicenter,randomized,controlled trial of electroacupuncture for perimenopause women with mild-moderate depression[J].BMRI,2018,2018(4):1-7.
[9]Michael C.HRT should be considered as first line therapy for perimenopausal depression:AGAINST:more clinical trials are needed[J].BJOG,2016,123(6):1011-1011.
[10]蔡胤浩,張亞華,范良敏.老年2型糖尿病合并抑郁癥患者炎癥因子及胰島素抵抗與抑郁嚴重程度的關系[J].中國老年學雜志,2015,35(22):6577-6578.
[11]陳寧貴,廖敏.解郁丸聯(lián)合西酞普蘭治療難治性抑郁癥的療效及其對血清去甲腎上腺素和5-羥色胺及腦源性神經(jīng)營養(yǎng)因子指標的影響研究[J].中國全科醫(yī)學,2017, 20(S2):338-340.
[12]司天梅,陳勝良,郝偉,等.5-HT1A受體參與常見精神疾病病理機制及5-HT1A受體部分激動劑的潛在治療效應研究進展[J].中國新藥與臨床雜志,2018,37(9):8-13.
[13]況雷雨,谷傳正,吉峰.阿戈美拉汀與5-HT再攝取抑制劑治療抑郁癥安全性的meta分析[J].中華行為醫(yī)學與腦科學雜志,2016,25(6):565-571.
[14]白樹新,李莉,王德斌,等.草酸艾司西酞普蘭聯(lián)合化瘀理氣清熱湯治療腦卒中后抑郁療效及對血清DA、5-HT及NE含量的影響[J].現(xiàn)代中西醫(yī)結合雜志,2017,26(15):1644-1646.
[15]劉岱岳,鐘明潔,任敏清,等.雌激素聯(lián)合抗抑郁藥物治療我國圍絕經(jīng)期婦女抑郁效果評價的Meta分析[J].重慶醫(yī)學,2017,46(24):3370-3374.
(收稿日期:2019-11-20? 本文編輯:祁海文)
[基金項目]江西省贛州市指導性科技計劃項目(GZ2016ZSF 231)